AstraZeneca vs Berkshire Hathaway: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and Berkshire Hathaway side by side

1. 1839Berkshire Hathaway

   Valley Falls Company Founded

   Oliver Chace founds the Valley Falls Company in Valley Falls, Rhode Island, as a cotton textile manufacturer. Chace had learned the trade working with Samuel Slater and built his first mill in 1806.

2. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

3. 1955Berkshire Hathaway

   Berkshire Fine Spinning and Hathaway Manufacturing Merge

   Berkshire Fine Spinning Associates and Hathaway Manufacturing combine and take the Berkshire Hathaway name.

4. 1962Berkshire Hathaway

   Buffett Partnership Buys Its First Berkshire Shares

   Buffett Partnership Ltd. buys its first Berkshire Hathaway shares in December 1962. Buffett was drawn to the pattern of Berkshire closing plants and using the liquidation proceeds to repurchase its own stock.

5. 1964Berkshire Hathaway

   Tender Offer Dispute With Seabury Stanton

   Berkshire president Seabury Stanton asks Buffett at what price Buffett Partnership would sell, agrees to $11.50 a share, then mails a tender offer at $11.375.

6. 1965Berkshire Hathaway

   Buffett Takes Control and Names Ken Chace President

   Buffett Partnership takes control of Berkshire Hathaway in May 1965 and Stanton leaves. Buffett selects Ken Chace, a long-time employee, as president to run the textile operation, and the cash it generates is pointed at other industries.

7. 1967Berkshire Hathaway

   Entry Into Insurance With National Indemnity

   Early in 1967 Berkshire pays $8.6 million to buy National Indemnity Company and a small sister insurer from owner Jack Ringwalt.

8. 1972Berkshire Hathaway

   See's Candies Bought for $25 Million

   Blue Chip Stamps, controlled by Buffett and Munger and later merged into Berkshire, buys See's Candies for $25 million.

9. 1985Berkshire Hathaway

   Textile Operations Closed

   Buffett decides in July 1985 to close Berkshire's textile operation and the shutdown is largely complete by year end. He described it as finally throwing in the towel after twenty years of unremitting struggle with the business.

10. 1993AstraZeneca

    Zeneca Group Spun Off from ICI

    Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

11. 1996Berkshire Hathaway

    GEICO Becomes Wholly Owned and Class B Shares Created

    Berkshire buys the remaining 49% of GEICO on January 2, 1996, having held 51%, and GEICO becomes a wholly owned subsidiary. Shareholders also approve a recapitalization creating Class B shares with the economic rights of one thirtieth of a Class A share.

12. 1998Berkshire Hathaway

    General Re and Executive Jet Acquired

    Berkshire acquires reinsurer General Re and fractional-aircraft operator Executive Jet.

13. 1999AstraZeneca

    Astra and Zeneca Merge to Form AstraZeneca

    The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

14. 2000AstraZeneca

    Nexium Launch Replaces Prilosec

    AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

15. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

16. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

17. 2010Berkshire Hathaway

    BNSF Railway Acquired

    Berkshire completes its purchase of Burlington Northern Santa Fe in the first quarter of 2010.

18. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

19. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

20. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

21. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

22. 2016Berkshire Hathaway

    Precision Castparts Acquired

    Berkshire completes the purchase of Precision Castparts, an aerospace and industrial components maker, for $235 a share in cash.

23. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

24. 2018Berkshire Hathaway

    Abel and Jain Named Vice Chairmen

    Berkshire's board expands from twelve to fourteen directors and elects Greg Abel and Ajit Jain.

25. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

26. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

27. 2022Berkshire Hathaway

    Alleghany Corporation Acquired

    Berkshire completes the acquisition of insurer Alleghany Corporation on October 19, 2022, paying $848.02 a share in cash for a total equity value of about $11.6 billion and adding the TransRe reinsurance business.

28. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

29. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

30. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

31. 2024Berkshire Hathaway

    Market Value Tops $1 Trillion

    Berkshire's market capitalization passes $1 trillion on August 28, 2024, making it the first US company outside the technology sector to reach that level.

32. 2024Berkshire Hathaway

    Pilot Travel Centers Fully Owned

    Berkshire acquires the remaining 20% of Pilot Travel Centers on January 16, 2024 and takes full ownership. It had bought 38.6% in 2017 and a further 41.4% for about $8.2 billion in January 2023.

33. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

34. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

35. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

36. 2025Berkshire Hathaway

    Board Approves Abel as CEO From January 2026

    Berkshire announces in May 2025 that Greg Abel will become President and Chief Executive Officer on January 1, 2026, with Warren Buffett remaining Chairman of the Board.

37. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

38. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

39. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

40. 2026Berkshire Hathaway

    Abel Becomes CEO and Buffett Becomes Chairman Emeritus

    Abel takes over as CEO on January 1, 2026 and Berkshire completes the $9.7 billion purchase of OxyChem from Occidental on January 2. On September 18, 2026 Buffett is named Chairman Emeritus and remains a director, and his son Howard G.

Acquisitions

Questions about AstraZeneca vs Berkshire Hathaway